Meta-Analysis
Copyright ©The Author(s) 2024.
World J Clin Cases. May 6, 2024; 12(13): 2218-2230
Published online May 6, 2024. doi: 10.12998/wjcc.v12.i13.2218
Table 1 Basic characteristics of included studies
Ref.
Sample size
Male (%)
Age (yr)
Disease duration (yr)
Intervention
Treatment duration (wk)
Left ventricular function
Type of CHF
Baseline cardiac disease
Bai and Li[19], 20234454.562.8 ± 5.310.6 ± 2.2Perindopril, metoprolol, trimetazidine, and YXST (0.18 g tid)4ICM
4452.362.0 ± 5.110.8 ± 2.4Perindopril, metoprolol, and trimetazidine4
Bai[20], 20195050.066.6 ± 10.4Telmisartan, amlodipine, and YXST (0.18 g tid)4ICM
5052.066.5 ± 10.2Telmisartan and amlodipine4
Cheng et al[21], 20194854.271.2 ± 3.6Levocarnitine and YXST (0.18 g tid)1Left ventricular diastolic dysfunctionHFpEF
4852.171.9 ± 3.8Levocarnitine1
Chen[22], 20192070.064.0 ± 11.0ACEI/ARB, MRA, diuretic, cardiotonic, and YXST (0.18 g tid)4
2085.063.0 ± 10.0ACEI/ARB, MRA, diuretic, and cardiotonic4
Fan et al[23], 20206352.466.0 ± 3.7Optimizing drug therapy and YXST (0.18 g tid)48
6357.167.0 ± 3.6Optimizing drug therapy48
Fu et al[26], 20146465.665.0 ± 10.22.4 ± 1.2ACEI, diuretic, cardiotonic, and YXST (0.18 g tid)12NICM
6264.564.0 ± 10.82.3 ± 1.4ACEI, diuretic, and cardiotonic12
Gu et al[25], 20166065.061.8 ± 11.8Perindopril, metoprolol, spironolactone, furosemide, isosorbide mononitrate, aspirin, clopidogrel, atorvastatin, and YXST (0.18 g tid)24
6070.062.5 ± 15.3Perindopril, metoprolol, spironolactone, furosemide, isosorbide mononitrate, aspirin, clopidogrel, and atorvastatin24
Gao and Zhang[24], 20213951.362.54 ± 7.5Benazepril, metoprolol, furosemide, digoxin, and YXST (0.18 g tid)24
3953.863.0 ± 6.8Benazepril, metoprolol, furosemide, and digoxin24
Huang et al[27], 20096358.759.8 ± 11.25.2 ± 4.3ACEI, β-blocker, diuretic, vasodilator, and YXST (0.18 g tid)4Left ventricular diastolic dysfunctionHFmrEF, HFpEF
6258.161.2 ± 13.45.0 ± 4.9ACEI, β-blocker, diuretic, and vasodilator4
Li and Zhou[28], 20196056.766.6 ± 12.55.7 ± 2.1Bisoprolol and YXST
(0.12 g tid)
24ICM
6043.364.9 ± 12.35.7 ± 2.0Bisoprolol24
Li[29], 20174753.261.35 ± 8.79.3 ± 3.6Diuretic, vasodilator, trimetazidine, statin, and YXST (0.18 g tid)4ICM
4751.261.58 ± 7.69.52 ± 2.9Diuretic, vasodilator, trimetazidine, and statin4
Liu[30], 20223348.558.4 ± 11.59.5 ± 3.1ACEI/ARB, β-blocker, MRA, diuretic, and YXST (0.18 g tid)12Left ventricular diastolic dysfunctionHFpEF
3243.857.1 ± 12.810.2 ± 3.7ACEI/ARB, β-blocker, MRA, and diuretic12
Qian and Wei[31], 201256ACEI, β-blocker, diuretic, vasodilator, cardiotonic, and YXST (0.12g tid)12NICM
56ACEI, β-blocker, diuretic, vasodilator, and vardiotonic12
Qu[32], 20088961.852.0 ± 13.1ACEI, β-blocker, diuretic, vasodilator, cardiotonic, and YXST (0.18g tid)24
8262.253.3 ± 18.3ACEI, β-blocker, diuretic, vasodilator, and cardiotonic24
Sun et al[35], 20163444.158.0 ± 13.1ACEI, β-blocker, diuretic, and YXST (0.18g tid)16
3452.954.3 ± 15.3ACEI, β-blocker, and diuretic16
Wang et al[33], 20113464.7Spironolactone, hydrochlorothiazide, nitroglycerin, dobutamine, and YXST (0.24 g tid)2
2669.2Spironolactone, hydrochlorothiazide, nitroglycerin, and dobutamine2
Yuan[34], 20124052.568.7 ± 10.23.2 ± 0.7ACEI, β-blocker, diuretic, vasodilator, and YXST (0.24 g tid)4Left ventricular diastolic dysfunctionHFpEF
3551.471.3 ± 13.12.9 ± 0.9ACEI, β-blocker, diuretic, and vasodilator4
Zhang and Niu[36], 20173452.955.7 ± 9.66.0 ± 3.3Benazepril, metoprolol, losartan potassium, hydrochlorothiazide, and YXST (0.18 g tid)8Left ventricular diastolic dysfunctionHFmrEF, HFpEF
3363.654.1 ± 9.66.1 ± 3.2Benazepril, metoprolol, losartan potassium, and hydrochlorothiazide8
Zhang[37], 20183060.063.8 ± 4.8ACEI, β-blocker, MRA, and YXST (0.18 g tid)12
3056.762.6 ± 5.2ACEI, β-blocker and MRA12
Zhang[38], 20222748.165.2 ± 5.35.2 ± 1.0ARNI/ARB, β-blocker, MRA, diuretic, vasodilator, cardiotonic, and YXST (0.18 g tid)8HFrEF
2758.664.1 ± 6.05.1 ± 1.2ARNI/ARB, β-blocker, MRA, diuretic, vasodilator, and cardiotonic8
Table 2 Meta-analysis results for efficacy endpoints of Yangxinshi tablet in treating heart failure with preserved ejection fraction
Outcome
Sample size
(E/C)
I2/%
MD/RR (95%CI)
P value
Clinical efficacy rate88/83371.19 (1.06-1.33)0.003
NT-proBNP48/480-0.73 (-0.95 to -0.51)< 0.00001
6-MWT121/1158044.61 (17.58-71.65)0.001